Equities Analysts Set Expectations for LSTA FY2025 Earnings

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Stock analysts at Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for shares of Lisata Therapeutics in a report released on Wednesday, January 21st. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($2.46) for the year, down from their prior forecast of ($2.09). Brookline Capital Management currently has a “Hold” rating on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share.

A number of other research analysts have also weighed in on the company. Zacks Research lowered Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Price Performance

Shares of LSTA stock opened at $4.11 on Friday. The business has a fifty day moving average of $2.15 and a 200 day moving average of $2.36. Lisata Therapeutics has a 1 year low of $1.81 and a 1 year high of $4.17. The firm has a market capitalization of $36.25 million, a price-to-earnings ratio of -1.93 and a beta of 1.11.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.05.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Ground Swell Capital LLC purchased a new stake in Lisata Therapeutics during the third quarter worth $62,000. CIBC Bancorp USA Inc. acquired a new position in shares of Lisata Therapeutics in the third quarter worth about $37,000. Finally, Cerity Partners LLC acquired a new position in shares of Lisata Therapeutics in the second quarter worth about $32,000. 8.94% of the stock is owned by institutional investors and hedge funds.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.